


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078A	APPLICATION NO. 09/616,622
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>		<p>RECEIVED</p> <p>AUG 17 2001</p>	
		<p>APPLICANT Hellstrand et al.</p>	<p>GROUP 1614 1644</p>
		<p>FILING DATE 07/14/00</p>	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1584	3,862,333	01/21/75	Chalupa et al.			
2	5,780,513	07/14/98	McDaniel et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
3	WO 96/10402	04/11/96	PCT				
4	WO 00/40229	07/13/00	PCT				

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
5			Gerami-Nejad et al. (1981) Aspects of the antibacterial action of diphenyliodonium chloride. Microbios. 30:97-107.

S:\DOCS\JMJM-6454.DOC\080301

EXAMINER <i>Ewdd</i>	DATE CONSIDERED 11/14/01
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	

RECEIVED

AUG 17 2001

TC 1700

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078A	APPLICATION NO. 09/616,622
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE July 14, 2000	GROUP 4614 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>SE</i>	1	5,348,739	09/20/94				

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	2	Alderson et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J.Exp.Med. 181:71-77.
	3	Allen et al. (1997) Morphological and biochemical characterization and analysis of apoptosis. JPM. 37:4:215-228
	4	Armstrong et al. (1998) Tumor antigen presentation: changing the rules. Cancer Immunol Immunother. 46:70-74
	5	Barna et al. (1983) Tumor-Enhancing effects of cimetidine. Oncology. 40:43-45.
	6	Bauer et al. (1998) Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J.Bio.Chem. 273:14:8048-8055.
	7	Barhoumi et al. (1993) concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. Cytometry. 14:747-756.
	8	Becker et al. (1996) T Cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J.Exp.Med. 183:2361-66.
	9	Beggins et al. (1998) Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. British J. of Haematology. 100:784-792.
	10	Bottazzi et al. (1992) Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility of IL-2 therapy of a murine melanoma ¹ . J.of Immuno. 148:1280-1285.
	11	Brunda et al. (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling nature killer cells. Int.J.Cancer. 40:365-371.
	12	Brune et al. (1996) Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. British J. of Haematology. 92:620-626.
	13	Birtin et al. (1981) The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bearing mice. Cancer letters. 12:195-201.
	14	Buttke et al. (1994) Oxidative stress as a mediator of apoptosis. Immunology Today. 15:1:7-10.
	15	Cao et al. (1998) Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Reserach. 58:1695-1699.
	16	Dohlsten et al. (1986) Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand.J.Immunol. 24:49-58.
	17	Dröge et al. (1994) Functions of glutathione and glutathione disulfide in immunology and immunopathology. The FASEB Journal. 8:1131-1138.
	18	Dumont et al. (1999) Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB. Oncogene. 18:747-757.
<i>SE</i>	19	Dutcher et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J.of clin.Onco. 7:4:477-485.

EXAMINER	<i>E. W. H.</i>	DATE CONSIDERED	11/14/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078A	APPLICATION NO. 09/616,622
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE July 14, 2000	GROUP 1644 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
582	20 Fao et al. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British J. of Haematology. 77:491-496.
	21 Hansson et al. (1996) Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. of Immuno. 42-47.
	22 Hawkins, M.J. (1993) Interleukin-2 antitumor and effector cell responses. Seminars in Oncology. 20:6:52-59.
	23 Hellstrand et al. (1986) Histamine h2-receptor-mediated regulation of human natural killer cell activity. J.of Immuno. 137:2:656-660.
	24 Hellstrand et al. (1990) Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int.Arch.Allergy App. Immuno. 92:379-389.
	25 Hellstrand et al. (1990) Role of histamine in natural killer cell-mediated resistance against tumor cells. J.of Immuno. 145:4365-4370.
	26 Hellstrand et al. (1991) Monocyte-induced down-modulation of CD16 and CD56 antigens on human natural killer cells and its regulation by histamine H2-receptors. Cellular Immuno. 138:44-54.
	27 Hellstrand et al. (1994) Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J. of Leukocyte Biology. 55:392-397.
	28 Hellstrand et al. (1994) Histaminergic regulation of NK cells. J. of Immuno. 153:4940-4947.
	29 Hellstrand et al. (1994) Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immuno.Immunother. 39:416-419.
	30 Hellstrand et al. (1995) Role of histamine in natural killer cell-dependent protection against herpes simplex virus type 2 infection in mice. Clin.Diagn.Lab.Immunol. 2:3:277-280.
	31 Hellstrand et al. (1997) Histamine and interleukin-2 in acute myelogenous leukemia. Leukemia and Lymphoma. 27:429-438.
	32 Johansson et al. (1998) The response of dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. British J. of Cancer. 77:8:1213-1219.
	33 Klebanoff, S.J. Oxygen-dependent cytotoxic mechanisms of phagocytes. Advances in Host Defense Mechanisms. 1:111-162.
	34 Kono et al. (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur.J.Immunol. 26:1308-1313.
	35 Lanier et al. (1988) Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the leu-23 activation antigen. J.Exp.Med. 167:1572-1585.
	36 Linden et al. (1987) Catalase and lipopolysaccharide enhance proliferation in the rat mixed lymphocyte reaction. Scand.J.Immunol. 26:223-228.
	37 Lundqvist et al. (1996) Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radical Biology & Medicine. 20:6:785-792.
	38 Mantovani et al. (1992) The origin and function of tumor-associated macrophages. Immunology Today. 13:7:265-270.
	39 Matsuda et al. (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int.J.Cancer. 61: 765-772.
	40 Medvediv et al. (1997) Regulation of fas and fas-ligand expression in NK cells by cytokines and the involvement of fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine. 9:6:394-404.
	41 Miesel et al. (1996) Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and nadph oxidase. Free Radical Biology & Medicine. 20:1:75-81.
	42 Mizoguchi et al. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1795-1798.
	43 Motzer et al. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research. 4:1183-1191.
	44 Nordlund et al. (1983) The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. J. of Investigative Dermatology. 81:1:28-31.
	45 Osband et al. (1981) Successful tumor immunotherapy with cimetidine in mice. The Lancet. 636-638.
582	46 Otsuji et al. (1996) Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 ξ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc.Natl.Acad.Sci. 93:13119-13124.

EXAMINER

Eudat

DATE CONSIDERED

11/14/07

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

<p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p>	<p>ATTY. DOCKET NO. MAXIM.078A</p>	<p>APPLICATION NO. 09/616,622</p>
<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>	<p>APPLICANT Hellstrand, et al.</p>	
<p>(USE SEVERAL SHEETS IF NECESSARY)</p>	<p>FILING DATE July 14, 2000</p>	<p>GROUP 1614 1644</p>

[illegible]

S:\DOCS\JJM\JJM-5079.DOC\112700

EXAMINER <i>E. Wood</i>	DATE CONSIDERED <i>11/14/07</i>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	